Title
Psychological distress with and without a history of depression: Results from the World Mental Health Japan 2nd Survey (WMHJ2)
Date Issued
15 March 2020
Access level
metadata only access
Resource Type
journal article
Author(s)
Nishi D.
Imamura K.
Watanabe K.
Ishikawa H.
Tachimori H.
Takeshima T.
Kawakami N.
The University of Tokyo
The University of Tokyo
The University of Tokyo
The University of Tokyo
The University of Tokyo
Publisher(s)
Elsevier B.V.
Abstract
Background: Psychological distress is prevalent and heterogenous. Checking a history of depression may contribute to identifying those who need intensive preventive support, but few studies have examined how different the dysfunction of people with and without a history of depression among those with psychological distress are. The study aimed to compare the two groups in physical health problems, level of social and familial support. Methods: The World Mental Health Japan 2nd Survey (WMHJ2), a cross-sectional, nationally representative face-to-face survey of residents aged 20–75 years old, was conducted from 2013 to 2015. We defined psychological distress as a K6 score of 5 or more. A history of major depressive disorder (MDD) was assessed by the WHO Composite International Diagnostic Interview version 3.0. Multinomial logistic regression analysis was used to examine the associations of sociodemographic characteristics, physical health problems, social support and mental health service use among those with no psychological distress, with psychological distress having no history of MDD, and with psychological distress having a history of MDD, adjusted for sociodemographic characteristics. Results: Unemployment, physical health problems, and lack of social support were much more common among those with psychological distress without a history of MDD than those with no psychological distress, and were largely comparable with those with psychological distress having a history of MDD. Limitations: The relatively low response rate might limit generalizability. Conclusions: The dysfunction in psychological distress without a history of MDD was largely equivalent to that seen in distress with a history of MDD.
Start page
545
End page
551
Volume
265
Language
English
OCDE Knowledge area
PsicologĂa
Scopus EID
2-s2.0-85075882656
PubMed ID
Source
Journal of Affective Disorders
Resource of which it is part
Journal of Affective Disorders
ISSN of the container
01650327
Sponsor(s)
The World Mental Health Japan 2nd Survey was supported by a Grant for Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labour and Welfare (H25-SEISHIN-IPPAN006) and by a Research and Development Grant for Comprehensive Research for Persons with Disabilities from the Japan Agency for Medical Research and Development (15dk0310020h0003). The WHO's World Mental Health Surveys are supported by the US National Institute of Mental Health (R01 MH070884), the MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13-MH066849, R01-MH069864 and R01 DA016558), the Fogarty International Center (R03-TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical Inc., GlaxoSmithKline, Bristol-Myers Squibb, and Shire.
The World Mental Health Japan 2nd Survey was supported by a Grant for Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labour and Welfare ( H25-SEISHIN-IPPAN006 ) and by a Research and Development Grant for Comprehensive Research for Persons with Disabilities from the Japan Agency for Medical Research and Development ( 15dk0310020h0003 ). The WHO's World Mental Health Surveys are supported by the US National Institute of Mental Health ( R01 MH070884 ), the MacArthur Foundation , the Pfizer Foundation , the US Public Health Service ( R13-MH066849 , R01-MH069864 and R01 DA016558 ), the Fogarty International Center ( R03-TW006481 ), the Pan American Health Organization , Eli Lilly and Company , Ortho-McNeil Pharmaceutical Inc. , GlaxoSmithKline , Bristol-Myers Squibb , and Shire .
Dr. Nishi reports personal fees from VOYAGE GROUP, Inc., personal fees from Startia, Inc., personal fees from en-power, Inc., personal fees from Seiko Instruments Inc., personal fees from MD.net, outside the submitted work. Dr. Kawakami reports grants from Inforcom Corp, grants from Fujitsu Software Technologies, grants from JMA, personal fees from Japan Productivity Center, personal fees from Occupational Health Foundation, personal fees from Japan Dental Association, personal fees from Sekisui Chemicals, personal fees from Junpukai Health Care Center, personal fees from Osaka Chamber of Commerce and Industry, outside the submitted work. The other authors have no conflicts of interest.
Dr. Nishi reports personal fees from VOYAGE GROUP, Inc., personal fees from Startia, Inc., personal fees from en-power, Inc., personal fees from Seiko Instruments Inc., personal fees from MD.net, outside the submitted work. Dr. Kawakami reports grants from Inforcom Corp, grants from Fujitsu Software Technologies, grants from JMA, personal fees from Japan Productivity Center, personal fees from Occupational Health Foundation, personal fees from Japan Dental Association, personal fees from Sekisui Chemicals, personal fees from Junpukai Health Care Center, personal fees from Osaka Chamber of Commerce and Industry, outside the submitted work. The other authors have no conflicts of interest.
Sources of information:
Directorio de ProducciĂłn CientĂfica
Scopus